Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trinity Biotech plc (TRIB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F annual reports and Form 6-K current reports. As a foreign private issuer listed on the Nasdaq Stock Market, Trinity Biotech uses these filings to furnish information on its human diagnostics and diabetes management business, financing arrangements and governance matters.
Form 6-K reports for TRIB frequently include press releases as exhibits, covering topics such as regulatory approvals for offshored and outsourced manufacturing of its TrinScreen HIV and Uni-Gold HIV rapid tests, expansion of its high-capacity HbA1c column system for the Premier Hb9210 analyzer, collaboration on epigenetic analysis for the EpiCapture prostate cancer test, and regulatory clearance for the PreClara Ratio preeclampsia testing service. Other 6-K filings reference amendments to credit agreements with Perceptive Credit Holdings entities, warrant issuances, and results of annual general meetings, including resolutions on auditor appointment and share capital authorities.
Users interested in Trinity Biotech’s capital structure and risk profile can review filings that discuss its term-loan facility, amendments and restatements of its credit agreement, and arrangements that allow potential conversion of portions of debt and certain obligations into equity. Filings also document interactions with Nasdaq regarding listing requirements, such as notices of non-compliance with minimum bid price and market value of publicly held shares thresholds, and subsequent confirmation that the company has regained compliance.
Stock Titan enhances access to these documents with tools that surface key elements of each filing, helping readers quickly identify material related to product approvals, financing terms, shareholder votes and other regulatory disclosures. This allows investors, analysts and other stakeholders to examine the official record of Trinity Biotech’s activities as reported to the U.S. Securities and Exchange Commission.
Trinity Biotech plc submitted a routine update that makes its full Annual Report 2024 available to investors. The company is also distributing key materials for its upcoming annual general meeting to holders of its ordinary shares.
The documents provided include the 2024 annual report, a letter from the company secretary, the formal notice of the annual general meeting, and a proxy card that allows shareholders to vote by proxy. These materials are intended to help shareholders review the company’s performance over the past year and participate in governance decisions at the meeting.
Trinity Biotech plc filed a Form 6-K to report that, as of September 2, 2025, it has regained compliance with Nasdaq Listing Requirements. This means the company once again meets the standards needed for its shares to remain listed on the Nasdaq market. The filing notes that this update was first announced in a press release, which is included as Exhibit 99.1. The document is also incorporated by reference into Trinity Biotech’s existing employee share plan registration statements on Form S-8.
Trinity Biotech plc filed a Form 6-K to furnish a press release announcing that it received regulatory approval to begin offshored and outsourced manufacturing of its flagship rapid HIV test. The company describes this step as supporting both strategic change and improved financial performance.
Trinity Biotech plc filed a report noting that it has received regulatory approval to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval allows the company to start providing a diagnostic testing service aimed at detecting preeclampsia, a serious pregnancy-related condition. The company communicated this development through a press release dated August 14, 2025, which is attached as an exhibit to the report.
Trinity Biotech reported breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, indicating a significant development in its product pipeline. The Form 6-K states the company issued a press release describing those trial results and filed it as Exhibit 99.1. The filing also discloses that on August 7, 2025 the company and certain subsidiaries amended and restated the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P. and that a warrant to purchase American Depositary Shares was issued in connection with that agreement. Copies of the press release, the Sixth Amended and Restated Credit Agreement and the warrant certificate are included as Exhibits 99.1, 99.2 and 99.3.
Trinity Biotech plc notified investors via Form 6-K that it issued a press release announcing the launch of an FDA-cleared Preeclampsia Testing Service. The company filed that press release as Exhibit 99.1 to the Form 6-K and stated the report is being incorporated by reference into its Form S-8 registration statements. The filing is signed by Chief Executive Officer John Gillard. The Form contains no financial results, pricing, partner or rollout details, and provides no operational or revenue metrics for the new service.
Trinity Biotech plc (TRIB) filed a Form 6-K to disclose that, on 24 Jul 2025, it released a press announcement for CGM+, an “AI-native” continuous-glucose-monitoring platform aimed at the estimated $260 bn global AI-wearable market. No financial metrics, guidance, or commercialization timelines were provided in the filing; the full press release is attached as Exhibit 99.1 but not reproduced here. The 6-K is incorporated by reference into the company’s existing S-8 registration statements.